NCT06108063View on ClinicalTrials.gov

Mitigation of Arthrofibrosis After Total Knee Arthroplasty Using Losartan

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

March 6, 2024

Primary Completion Date

June 30, 2027

Study Completion Date

June 30, 2027

Conditions
Knee Arthroplasty, Total
Interventions
DRUG

Losartan

12.5 mg oral Losartan taken for 28 days total (4 week postoperative).

DRUG

Placebo - Losartan

Losartan appearance-matched Prosolv EasyTab SP placebo. 12.5 mg oral tablet taken for 28 days total (4 week postoperative).

Trial Locations (1)

81657

RECRUITING

The Steadman Clinic, Vail

All Listed Sponsors
lead

Steadman Philippon Research Institute

OTHER